Menu
Back to User profile » Professor christos chouaid
Papers published by Professor christos chouaid:
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
Auliac JB, Guisier F, Bizieux A, Assouline P, Bernardini M, Lamy R, Justeau G, François G, Damotte D, Chouaïd C
OncoTargets and Therapy 2020, 13:13299-13305
Published Date: 30 December 2020
Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
Bylicki O, Paleiron N, Assié JB, Chouaïd C
OncoTargets and Therapy 2020, 13:5691-5706
Published Date: 17 June 2020
Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy
Dalon F, Devouassoux G, Belhassen M, Nachbaur G, Correia Da Silva C, Sail L, Jacoud F, Chouaid C, Van Ganse E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2905-2915
Published Date: 16 December 2019
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C
OncoTargets and Therapy 2018, 11:4051-4064
Published Date: 16 July 2018
Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S
ClinicoEconomics and Outcomes Research 2017, 9:655-668
Published Date: 25 October 2017
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C
ClinicoEconomics and Outcomes Research 2017, 9:505-518
Published Date: 16 August 2017
Cost analysis of adverse events associated with non-small cell lung cancer management in France
Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E
ClinicoEconomics and Outcomes Research 2017, 9:443-449
Published Date: 27 July 2017
Targeted therapy for localized non-small-cell lung cancer: a review
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, Chouaïd C
OncoTargets and Therapy 2016, 9:4099-4104
Published Date: 5 July 2016
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
Chouaïd C, Crequit P, Borget I, Vergnenegre A
ClinicoEconomics and Outcomes Research 2015, 7:9-15
Published Date: 15 December 2014
Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
Vergnenègre A, Borget I, Chouaid C
ClinicoEconomics and Outcomes Research 2013, 5:137-141
Published Date: 10 April 2013
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:31-37
Published Date: 26 January 2012